JP2015078220A5 - - Google Patents

Download PDF

Info

Publication number
JP2015078220A5
JP2015078220A5 JP2014249071A JP2014249071A JP2015078220A5 JP 2015078220 A5 JP2015078220 A5 JP 2015078220A5 JP 2014249071 A JP2014249071 A JP 2014249071A JP 2014249071 A JP2014249071 A JP 2014249071A JP 2015078220 A5 JP2015078220 A5 JP 2015078220A5
Authority
JP
Japan
Prior art keywords
clostridium difficile
caused
composition
bibenzo
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014249071A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015078220A (ja
Filing date
Publication date
Priority claimed from GBGB0821913.1A external-priority patent/GB0821913D0/en
Application filed filed Critical
Publication of JP2015078220A publication Critical patent/JP2015078220A/ja
Publication of JP2015078220A5 publication Critical patent/JP2015078220A5/ja
Pending legal-status Critical Current

Links

JP2014249071A 2008-12-02 2014-12-09 抗細菌化合物 Pending JP2015078220A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0821913.1 2008-12-02
GBGB0821913.1A GB0821913D0 (en) 2008-12-02 2008-12-02 Antibacterial compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2011538052A Division JP5665756B2 (ja) 2008-12-02 2009-12-01 抗細菌化合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016212160A Division JP2017048217A (ja) 2008-12-02 2016-10-28 抗細菌化合物

Publications (2)

Publication Number Publication Date
JP2015078220A JP2015078220A (ja) 2015-04-23
JP2015078220A5 true JP2015078220A5 (enExample) 2015-12-24

Family

ID=40262471

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011538052A Active JP5665756B2 (ja) 2008-12-02 2009-12-01 抗細菌化合物
JP2014249071A Pending JP2015078220A (ja) 2008-12-02 2014-12-09 抗細菌化合物
JP2016212160A Pending JP2017048217A (ja) 2008-12-02 2016-10-28 抗細菌化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2011538052A Active JP5665756B2 (ja) 2008-12-02 2009-12-01 抗細菌化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016212160A Pending JP2017048217A (ja) 2008-12-02 2016-10-28 抗細菌化合物

Country Status (27)

Country Link
US (3) US8975416B2 (enExample)
EP (3) EP2907813B1 (enExample)
JP (3) JP5665756B2 (enExample)
KR (1) KR101643435B1 (enExample)
CN (1) CN102227411B (enExample)
AU (1) AU2009323854B2 (enExample)
BR (2) BR122020013025B1 (enExample)
CA (1) CA2744962C (enExample)
CY (2) CY1116383T1 (enExample)
DK (2) DK2907813T3 (enExample)
ES (2) ES2537059T3 (enExample)
GB (1) GB0821913D0 (enExample)
HR (2) HRP20150518T1 (enExample)
HU (1) HUE029151T2 (enExample)
IL (1) IL213325A (enExample)
LT (1) LT2907813T (enExample)
MX (1) MX2011005837A (enExample)
NZ (1) NZ593111A (enExample)
PL (2) PL2373631T3 (enExample)
PT (2) PT2907813T (enExample)
RS (1) RS54904B1 (enExample)
RU (1) RU2525915C2 (enExample)
SG (1) SG171939A1 (enExample)
SI (2) SI2373631T1 (enExample)
SM (2) SMT201500117B (enExample)
WO (1) WO2010063996A2 (enExample)
ZA (1) ZA201103751B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
GB2480813A (en) * 2010-06-01 2011-12-07 Summit Corp Plc Compounds for the treatment of clostridium difficile-associated disease
WO2011151619A1 (en) * 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
GB2480816A (en) * 2010-06-01 2011-12-07 Summit Corp Plc Compounds for the treatment of Clostridium difficile associated diseases
GB2480814A (en) * 2010-06-01 2011-12-07 Summit Corp Plc Compounds for the treatment of clostridium difficile-associated disease
WO2011151620A1 (en) * 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
SI2575968T1 (sl) * 2010-06-01 2016-06-30 Summit Therapeutics Plc Spojine za zdravljenje bolezni, ki je povezana s clostridium difficile
US9079935B2 (en) 2012-08-13 2015-07-14 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Reducing risk of contracting Clostridium-difficile associated disease
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
DK3628161T3 (da) 2012-11-23 2023-05-30 Seres Therapeutics Inc Synergistiske bakterielle sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf
AU2014212004B2 (en) 2013-02-04 2018-09-20 Société des Produits Nestlé S.A. Compositions for treating or preventing or reducing the severity of clostridium difficile related diseases
WO2014121304A1 (en) 2013-02-04 2014-08-07 Seres Health, Inc. Compositions and methods
EP2967077A4 (en) 2013-03-15 2016-09-14 Seres Therapeutics Inc NETWORK-BASED MICROBIAL COMPOSITIONS AND METHOD
KR102611070B1 (ko) 2013-11-25 2023-12-07 세레스 테라퓨틱스, 인코포레이티드 상승적 박테리아 조성물 및 그것의 생산 방법 및 용도
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
JP6526956B2 (ja) * 2013-12-19 2019-06-05 花王株式会社 固形状組成物
US9717711B2 (en) 2014-06-16 2017-08-01 The Lauridsen Group Methods and compositions for treating Clostridium difficile associated disease
US20180000793A1 (en) 2015-02-06 2018-01-04 Ernesto Abel-Santos Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis
MX2020001774A (es) 2017-08-14 2020-09-09 Seres Therapeutics Inc Composiciones y métodos para tratar enfermedad colestásica.
EP3692030B1 (en) * 2017-10-05 2023-04-19 Sandoz AG Process for the preparation of ridinilazole using acid addition salts
BR112020008552A2 (pt) 2017-10-30 2020-12-29 Seres Therapeutics, Inc. métodos e composições para tratamento de resistência a antibiótico
MX2022000598A (es) 2019-07-17 2022-03-04 Summit Oxford Ltd Preparacion de compuestos antibacterianos.
DK4069691T3 (da) 2019-12-06 2024-10-28 Vertex Pharma Substituerede tetrahydrofuraner som modulatorer af natriumkanaler
US20210324009A1 (en) * 2020-04-17 2021-10-21 The University Of Hong Kong Anti-bacterial calcium-dependent antibiotic (cda) analogs and methods of treating bacterial infections
GB202100471D0 (en) 2021-01-14 2021-03-03 Summit Oxford Ltd Preparation of antibacterial compounds
GB202100470D0 (en) * 2021-01-14 2021-03-03 Summit Oxford Ltd Solid tablet dosage for of ridinilazole
MX2023013980A (es) * 2021-05-24 2024-03-05 Aimmax Therapeutics Inc Combinaciones de pristinamicina ia y flopristin para el tratamiento o prevencion de infecciones bacterianas.
MA64853B1 (fr) 2021-06-04 2025-11-28 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hétéro)aryl) tétrahydrofuran carboxamides utilisés en tant que modulateurs de canaux sodiques
JP7728367B2 (ja) 2021-06-14 2025-08-22 スコーピオン・セラピューティクス・インコーポレイテッド がんを処置するために使用され得る尿素誘導体
WO2023039159A2 (en) 2021-09-09 2023-03-16 Abel Santos Ernesto Inhibitors of c. difficile spore germination
WO2024112631A1 (en) * 2022-11-22 2024-05-30 Aimmax Therapeutics, Inc. Streptogramin a monotherapy for treating or preventing bacterial infections
EP4418810A1 (de) 2023-02-15 2024-08-21 Siemens Aktiengesellschaft Verfahren zur rechnergestützten überwachung einer industriellen anlage mittels eines funknetzes

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3661849A (en) * 1965-10-06 1972-05-09 Ashland Oil Inc Heterocyclic polyimides prepared from heterocyclic diamines
US3503929A (en) 1965-10-21 1970-03-31 Minnesota Mining & Mfg Polyimidazoquinazolines and polyamidobenzimidazoles
DE1670684A1 (de) 1966-04-01 1970-12-03 Hoechst Ag Verfahren zur Herstellung von basisch substituierten Bis-benzimidazol-derivaten
US4087409A (en) * 1966-11-07 1978-05-02 Monsanto Company Ordered heterocyclic copolymers
JPS50140445A (enExample) * 1974-04-30 1975-11-11
JPS50154250A (enExample) * 1974-05-31 1975-12-12
JPH03500661A (ja) * 1988-06-09 1991-02-14 ザ・ダウ・ケミカル・カンパニー ベンゾキサゾール，ベンゾチアゾールまたはベンズイミダゾールの少なくとも１つの結合によって架橋したビスシクロブタレンのモノマー，オリゴマー及びポリマー
US5089592A (en) 1988-06-09 1992-02-18 The Dow Chemical Company Biscyclobutarene monomer comprising two cyclobutarene moieties bridged by a divalent radical comprising at least one benzothiazole or benzimidazole linkage
GB9108279D0 (en) * 1991-04-18 1991-06-05 Ucb Sa A method of preparing 1h-benzimidazoles
US5317078A (en) * 1991-10-30 1994-05-31 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Polybenzimidazole via aromatic nucleophilic displacement
FI972090L (fi) 1994-11-17 1997-05-15 Hoffmann La Roche Antibakteeriset dibentsimidatsolijohdannaiset
CN1164227A (zh) * 1994-11-17 1997-11-05 弗·哈夫曼-拉罗切有限公司 联苯并咪唑衍生物
US5770617A (en) 1996-03-20 1998-06-23 Rutgers, The State University Of New Jersey Terbenzimidazoles useful as antifungal agents
JPH11158158A (ja) * 1997-12-03 1999-06-15 Snow Brand Milk Prod Co Ltd 新規ベンゾイミダゾール誘導体
JPH11158156A (ja) 1997-12-03 1999-06-15 Earth Chem Corp Ltd 新規な１−（４−アルキルオキシフェニル）イミダゾール化合物
US6358930B1 (en) 1998-05-28 2002-03-19 Synsorb Biotech Inc. Treatment of C. difficile toxin B associated conditions
JP2000095767A (ja) * 1998-09-28 2000-04-04 Takeda Chem Ind Ltd 性腺刺激ホルモン放出ホルモン拮抗剤
GB9908828D0 (en) 1999-04-16 1999-06-16 Univ Reading The Compounds
ATE284874T1 (de) 2000-11-27 2005-01-15 Ciba Sc Holding Ag Substituierte 5-aryl- und 5-heteroaryl-2-(2- hydroxyphenyl)-2h-benzotriazolderivate als uv- absorbierende substanzen
BR0116216A (pt) 2000-12-15 2004-08-17 Vertex Pharma Inibidores de girase e seus usos
FR2819180B1 (fr) 2001-01-11 2003-02-21 Oreal Composition photoprotectrices a base de polymeres amphiphiles d'au moins un monomere a insaturation ethylique a groupement sulfonique et comportant une partie hydrophobe
AU2002228317A1 (en) 2001-01-29 2002-08-12 Insight Strategy And Marketing Ltd Benz-1,3-azole derivatives and their uses as heparanase inhibitors
CA2445515A1 (en) 2001-05-04 2002-11-04 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
AU2002317377A1 (en) * 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
MXPA04003954A (es) 2001-10-26 2004-11-29 Aventis Pharma Inc Bencimidazoles.
CA2489128C (en) 2002-06-13 2012-01-03 Vertex Pharmaceuticals Incorporated 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase iv inhibitors for the treatment of bacterial infections
AU2003261834A1 (en) * 2002-08-30 2004-05-04 Bf Research Institute, Inc. Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein
JP2006513162A (ja) 2002-11-01 2006-04-20 パラテック ファーマシューティカルズ インコーポレイテッド 転写因子調節化合物およびその使用方法
AU2005324492B2 (en) 2004-04-23 2012-06-07 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
KR100629060B1 (ko) 2004-08-11 2006-09-26 주식회사 엘지화학 새로운 벤즈이미다졸계 화합물
EP1812440B1 (en) 2004-11-04 2010-09-22 Vertex Pharmaceuticals, Inc. Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
WO2006077412A1 (en) 2005-01-19 2006-07-27 Biolipox Ab Thienopyrroles useful in the treatment of inflammation
US7825154B2 (en) 2005-08-12 2010-11-02 The United States Of America As Represented By The Secretary Of The Army Small molecule inhibitors of botulinum neurotoxins
CN101321744A (zh) 2005-11-07 2008-12-10 沃泰克斯药物股份有限公司 作为回旋酶抑制剂的苯并咪唑衍生物
KR100744827B1 (ko) * 2006-04-05 2007-08-01 한국화학연구원 트리플루오로비닐옥시기를 포함하는 불소계 벤즈이미다졸 단량체 및 이의 제조방법
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
SG174086A1 (en) 2006-08-30 2011-09-29 Cellzome Ltd Triazole derivatives as kinase inhibitors
AR063311A1 (es) 2006-10-18 2009-01-21 Novartis Ag Compuestos organicos
WO2008073451A2 (en) 2006-12-11 2008-06-19 Sirtris Pharmaceuticals, Inc. Benzoimidazole derivatives as sirtuin (sir) modulating compounds
EP2121626A1 (en) 2006-12-15 2009-11-25 Pfizer Products Inc. Benzimidazole derivatives
WO2009147189A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Novel compounds
KR101022649B1 (ko) 2008-08-07 2011-03-22 삼성모바일디스플레이주식회사 헤테로고리 화합물 및 이를 이용한 유기 전계 발광 장치
US7906655B2 (en) 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
CN102427731B (zh) 2009-02-27 2015-05-13 英安塔制药有限公司 丙型肝炎病毒抑制剂
KR101219487B1 (ko) 2009-03-03 2013-01-15 덕산하이메탈(주) 비스벤조이미다졸 화합물 및 이를 이용한 유기전기소자, 그단말
SI2414369T1 (sl) 2009-04-02 2015-12-31 Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii Derivati imidazo(2,1-b)(1,3,4)tiadiazola
US8536180B2 (en) 2009-05-27 2013-09-17 Abbvie Inc. Pyrimidine inhibitors of kinase activity
CA2763140A1 (en) 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
JP5744859B2 (ja) 2009-06-15 2015-07-08 ライジェル ファーマシューティカルズ， インコーポレイテッド 脾臓チロシンキナーゼ（ｓｙｋ）の小分子阻害薬
WO2011046954A1 (en) 2009-10-13 2011-04-21 Ligand Pharmaceuticals Inc. Hematopoietic growth factor mimetic small molecule compounds and their uses
SI2575968T1 (sl) 2010-06-01 2016-06-30 Summit Therapeutics Plc Spojine za zdravljenje bolezni, ki je povezana s clostridium difficile

Similar Documents

Publication Publication Date Title
JP2015078220A5 (enExample)
WO2017087608A8 (en) Modulators of ror-gamma
EA033544B1 (ru) Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret)
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
MY192521A (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
JP2016515522A5 (enExample)
WO2015200481A8 (en) Mnk inhibitors and methods related thereto
SG10201902598VA (en) Peptidomimetic macrocycles and formulations thereof
UA114906C2 (uk) Гетероциклільні сполуки як інгібітори мек
IL295418B1 (en) Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus
HUE052332T2 (hu) Heteroaril-származék vagy gyógyászatilag elfogadható sója, eljárás annak elõállítására, és az ezeket hatóanyagént tartalmazó gyógyászati készítmény PI3 kinázokkal összefüggõ betegségek megelõzésére vagy kezelésére
PH12016502103A1 (en) Novel disubstituted 1,2, 4-triazine compound
HK1217092A1 (zh) 治疗性化合物及其用途
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
PH12017500089B1 (en) Aldosterone synthase inhibitors
WO2015173701A3 (en) Pharmaceutical compositions comprising danirixin for treating infectious diseases
WO2016011049A3 (en) Compositions and methods for disease treatment using nanoparticle delivered compounds
CN109689652A (zh) 稠杂环类衍生物、其制备方法及其在医学上的应用
WO2016010869A3 (en) FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS
PH12016500042A1 (en) Stabilized pharmaceutical dosage forms comprising atrasentan
PH12018500358A1 (en) Compounds for use in an antibacterial applications
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
EA201692518A3 (ru) Способы улучшения производительности миокарда у пациентов после операции фонтена с применением композиций уденафила
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof